Renal Effects and Metabolism of Sevoflurane in Fischer 344 Rats:

An In-vivo and In-vitro Comparison with Methoxyflurane

Thomas L. Cook, M.D.,* William J. Beppu, M.D.,* Ben A. Hitt, Ph.D.,†
Jon C. Kosek, M.D.,‡ Richard I. Mazze, M.D.§

Sevoflurane, 1.4 per cent (MAC), was administered to groups of Fischer 344 rats for 10 hours, 4 hours, or 1 hour; additional rats received 0.5 per cent methoxyflurane for 3 hours or 1 hour. Urinary inorganic fluoride excretion of sevoflurane in ceto was a third to a fourth that of methoxyflurane. However, using hepatic microsomes, sevoflurane and methoxyflurane were defluorinated in vitro at essentially the same rate. The discrepancy between defluorination of sevoflurane and methoxyflurane in ceto and in vitro was probably due to differences in tissue solubility between the drugs. There were no renal functional or morphologic defects following sevoflurane administration. An unexplained adverse effect was significant weight loss, which occurred following all exposures to sevoflurane. (Key words: Anesthetics, volatile, sevoflurane; Anesthetics, volatile, methoxyflurane; Biotransformation, sevoflurane; Kidney, nephrotoxicity.)

SEVOFLURANE® (CH₂F-O-CH(CF₃); fluoromethyl-1,1,1,3,3,3-hexafluoro-isopropyl ether) is a new, nonflammable, fluorinated inhalation anesthetic agent with the following properties: empirical formula, C₂H₂F₂O; boiling point (760 torr), 58.5 C; liquid density, 1.505 g/ml; vapor pressure (20 C), 160 torr; blood-gas partition coefficient, 0.59;

* Research Fellow in Anesthesiology.
† Research Associate in Anesthesiology.
‡ Associate Professor of Clinical Pathology.
§ Associate Professor of Anesthesiology.

Received from the Departments of Anesthesia and Pathology, Stanford University School of Medicine, Stanford, California 94305, and Veterans Administration Hospital, Palo Alto, California 94304. Accepted for publication March 5, 1975. Supported in part by the Veterans Administration Hospital, Palo Alto, California 94304, and Travenol Laboratories, Inc., Morton Grove, Illinois 60053.

Address reprint requests to: Richard I. Mazze, M.D., Chief, Anesthesiology Service (112A), VA Hospital, 3801 Miranda Avenue, Palo Alto, California 94303.


oil-gas partition coefficient (corn oil), 55; and MAC, 2.5 per cent.** As part of the animal experiments carried out before an investigational drug is used in man, the renal effects and biotransformation of sevoflurane in vivo and in vitro were studied in Fischer 344 rats.

Methods and Materials

IN-VIVO STUDIES

Thirty 12-month-old, male Fischer 344 rats were divided at random into five treatment groups of six rats each, as follows: Group I, no anesthesia; Group II, 0.5 per cent methoxyflurane for 3 hours; Group III, 0.5 per cent methoxyflurane for 1 hour; Group IV, 1.4 per cent sevoflurane†† for 10 hours; Group V, 1.4 per cent sevoflurane for 4 hours. At a later date six additional 12-month-old male Fischer 344 rats received 1.4 per cent sevoflurane for 1 hour. All animals were treated identically except as noted in their group designations. Animals were housed in individual metabolic cages where food and tap water containing inorganic fluoride, 21 mg/kg, and one part per million (52.6 μM), respectively, were allowed ad libitum. Artificial light was present from 7 AM to 6 PM each day, and room temperature was maintained at 21–23 C. Three days were allowed for the animals to adapt to the metabolic cages; during this time a 1-ml tail blood sample was obtained for control blood tests. On each of days 4 through 6, control 24-hour urine collections were obtained. On experiment day 7, sevoflurane was administered to the rats in a plastic chamber of 100-liter volume. In order to conserve drug, a closed system was

** Unpublished data, Mazze et al.
†† MAC in mice was reported as 1.4 vol per cent; this value was utilized in the present study. Subsequently, we determined MAC to be 2.5 vol per cent in Fischer 344 rats.
employed. Soda lime was placed on the floor of the anesthesia chamber to a depth of ½ inch and a plastic wire mesh laid on top of it. After the rats were in the chamber, 10 ml of liquid sevoflurane were injected onto a gauze sponge and vaporized within the chamber. Ambient sevoflurane concentration was measured by gas chromatography, and 2-5-ml increments of drug were vaporized approximately every 15 minutes in order to maintain a concentration of 1.4 per cent. Oxygen was added to the chamber, intermittently, in order to maintain an atmospheric concentration of 50 per cent. Methoxyflurane was administered with a Pentec vaporizer employing a semiclosed system; oxygen flowing at 6 l/min was the carrier gas.

Anesthetic concentrations in the cage were determined with a Varian No. 1440 gas chromatograph and oxygen concentration with an Instrumentation Laboratories No. 402 oxygen analyzer. Rectal temperature was continuously monitored with a Yellow Springs multichannel telethermometer and was maintained between 37 and 39 C with the aid of a water mattress on the floor of the chamber. During the last 30 minutes of anesthesia, a 0.3-ml blood specimen was obtained from the tail of each animal in order to measure anesthetic concentration, pH, PaO₂, and PCO₂. After anesthesia, rats received 100 per cent oxygen until awake and then were returned to their individual metabolic cages, where 24-hour urine collections were continued for the next four days. One-milliliter tail blood samples were obtained on post-anesthesia days 1 and 2; feces were collected on day 1. Two rats from each group were sacrificed at the end of experiment day 7 (postanesthesia day 1), and the remaining animals were sacrificed at the end of postanesthesia day 4. At the time of sacrifice, blood was obtained for biochemical analysis, and kidney tissue was removed for study by light and electron microscopy. Serum and urine specimens were analyzed for sodium and potassium (Instrumentation Laboratories No. 143 Flame Photometer), urea nitrogen (Technicon AutoAnalyzer), fluoride activity (Orion ion-specific fluoride electrode and No. 801 I onalyzer), and osmolality (Fiske Model 130 Osmometer). Urinary organic fluoride was determined employing a combustion method. Laboratory methods have been reported.2-5 Fecal inorganic fluoride activity was determined by placing samples in 100-ml flasks containing 50 ml of 2.5 M sodium acetate buffer, pH 4.8. Each sample was then homogenized and analyzed for fluoride ion activity. Sodium, potassium, osmolal, inorganic and organic fluoride excretions were calculated, as was urea nitrogen clearance. Rats were weighed daily.

**PEAK SERUM FLUORIDE**

Six additional Fischer 344 rats were anesthetized with 1.4 per cent sevoflurane for 4 hours. Tail blood was obtained 1, 4, 12, 24, and 48 hours after anesthesia and serum inorganic fluoride activity was determined.

**IN-VITRO STUDIES**

Hepatic microsomes were prepared from seven adult male Fischer 344 rats, using standard methods.4,5 In the final reaction mixture, 5 mg of microsomal protein were incubated with 1 mM sevoflurane or methoxyflurane in the presence of oxygen and a NADPH-generating system. The reaction was stopped after 30 minutes and the mixture was vacuum-evaporated to dryness. The residue was resuspended in acetate buffer and inorganic fluoride concentration determined.

**STATISTICAL ANALYSIS**

The mean value of each variable for each rat for the three-day postanesthetic period was calculated and means were determined for each group. Daily means of postanesthetic data were computed for each group and compared with the preanesthetic mean. The effects of increasing methoxyflurane and sevoflurane dosages were determined by subtracting the preanesthetic mean from the mean of determinations for each postanesthetic day. These values were compared with those of unanesthetized control rats, Group I, for the same periods. Student’s t test was used for statistical analysis.

**Results**

**IN-VIVO STUDIES**

Prior to anesthesia all variables for all groups were within normal limits. There
<table>
<thead>
<tr>
<th>Table 1. Serum and Urinary Values, Mean ± SE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Period</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Group I, control</td>
</tr>
<tr>
<td>Preanesthetic*</td>
</tr>
<tr>
<td>Postanesthetic*</td>
</tr>
<tr>
<td>Group II, 0.5 per cent Methoxyflurane, 3 hours</td>
</tr>
<tr>
<td>Preanesthetic</td>
</tr>
<tr>
<td>Postanesthetic</td>
</tr>
<tr>
<td>Group III, 0.5 per cent Methoxyflurane, 1 hour</td>
</tr>
<tr>
<td>Preanesthetic</td>
</tr>
<tr>
<td>Postanesthetic</td>
</tr>
<tr>
<td>Group IV, 1.4 per cent Sevoflurane, 10 hours</td>
</tr>
<tr>
<td>Preanesthetic</td>
</tr>
<tr>
<td>Postanesthetic</td>
</tr>
<tr>
<td>Group V, 1.4 per cent Sevoflurane, 4 hours</td>
</tr>
<tr>
<td>Preanesthetic</td>
</tr>
<tr>
<td>Postanesthetic</td>
</tr>
<tr>
<td>Group VI, 1.4 per cent Sevoflurane, 1 hour</td>
</tr>
<tr>
<td>Preanesthetic</td>
</tr>
<tr>
<td>Postanesthetic</td>
</tr>
</tbody>
</table>

* Rats in this group were not anesthetized. Collection periods parallel those for anesthetized rats.

↑ P < 0.05, preanesthetic (days 3-6) vs. postanesthetic (day 7).

‡ P < 0.01, preanesthetic (days 3-6) vs. postanesthetic (day 7).

§ P < 0.05, postanesthetic (day 7) vs. postanesthetic, control group (day 7).

¶ P < 0.01, postanesthetic (day 7) vs. postanesthetic, control group (day 7).
<table>
<thead>
<tr>
<th>Period</th>
<th>Urea Volume (mL/24 hr)</th>
<th>Sodium Excretion (mEq/24 hr)</th>
<th>Potassium Excretion (mEq/24 hr)</th>
<th>Uric Acid Excretion (mg/24 hr)</th>
<th>Inorganic Fluoride Excretion (μM/24 hr)</th>
<th>Organic Fluoride Excretion (μM/24 hr)</th>
<th>Urea Clearance (mL/min)</th>
<th>Fecal Inorganic Fluoride (μM/24 hr)</th>
<th>Body Weight (g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group 1, control</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preanesthetic*</td>
<td>8.9 ± 0.3</td>
<td>1.2 ± 0.1</td>
<td>2.0 ± 0.1</td>
<td>19.7 ± 0.6</td>
<td>4.2 ± 0.4</td>
<td>10.5 ± 1.4</td>
<td>4.1 ± 0.1</td>
<td>1.7 ± 0.1</td>
<td>387 ± 4</td>
</tr>
<tr>
<td>Postanesthetic*</td>
<td>8.3 ± 0.3</td>
<td>1.3 ± 0.1</td>
<td>3.1 ± 0.5</td>
<td>19.7 ± 0.5</td>
<td>4.9 ± 0.2</td>
<td>5.3 ± 0.2</td>
<td>4.0 ± 0.1</td>
<td>1.5 ± 0.0</td>
<td>381 ± 7</td>
</tr>
<tr>
<td>Group II, 0.5 per cent Methoxyflurane, 3 hours</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preanesthetic</td>
<td>10.9 ± 0.6</td>
<td>1.5 ± 0.1</td>
<td>3.4 ± 0.1</td>
<td>22.3 ± 0.8</td>
<td>5.1 ± 0.2</td>
<td>7.8 ± 0.7</td>
<td>1.8 ± 0.1</td>
<td>—</td>
<td>317 ± 7</td>
</tr>
<tr>
<td>Postanesthetic</td>
<td>16.9</td>
<td>1.7</td>
<td>3.1</td>
<td>23.5</td>
<td>9.1</td>
<td>417.8</td>
<td>1.7</td>
<td>1.4</td>
<td>391</td>
</tr>
<tr>
<td>Group III, 0.5 per cent Methoxyflurane, 1 hour</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preanesthetic</td>
<td>10.9 ± 0.4</td>
<td>1.5 ± 0.1</td>
<td>3.5 ± 0.1</td>
<td>23.9 ± 0.9</td>
<td>5.1 ± 0.2</td>
<td>8.4 ± 0.8</td>
<td>1.8 ± 0.1</td>
<td>—</td>
<td>301 ± 14</td>
</tr>
<tr>
<td>Postanesthetic</td>
<td>11.5 ± 0.5</td>
<td>1.7</td>
<td>3.4</td>
<td>24.1</td>
<td>58.8</td>
<td>250.7</td>
<td>1.7</td>
<td>1.2</td>
<td>387</td>
</tr>
<tr>
<td>Group IV, 1.4 per cent Sevoflurane, 10 hours</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preanesthetic</td>
<td>9.4 ± 0.5</td>
<td>1.5</td>
<td>3.2</td>
<td>21.5</td>
<td>4.8</td>
<td>3.0</td>
<td>1.6</td>
<td>—</td>
<td>399 ± 5</td>
</tr>
<tr>
<td>Postanesthetic</td>
<td>5.0</td>
<td>0.6</td>
<td>1.4</td>
<td>9.4</td>
<td>38.2</td>
<td>142.9</td>
<td>0.8</td>
<td>0.9</td>
<td>399</td>
</tr>
<tr>
<td>Group V, 1.4 per cent Sevoflurane, 4 hours</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preanesthetic</td>
<td>10.3 ± 0.6</td>
<td>1.5</td>
<td>3.1</td>
<td>20.9</td>
<td>4.7</td>
<td>8.3</td>
<td>1.6</td>
<td>—</td>
<td>406 ± 7</td>
</tr>
<tr>
<td>Postanesthetic</td>
<td>9.8± 1.4</td>
<td>1.1</td>
<td>2.5</td>
<td>18.1</td>
<td>41.4</td>
<td>193.6</td>
<td>1.4</td>
<td>0.7</td>
<td>387</td>
</tr>
<tr>
<td>Group VI, 1.4 per cent Sevoflurane, 1 hour</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preanesthetic</td>
<td>7.3 ± 0.2</td>
<td>0.9</td>
<td>2.8</td>
<td>17.0</td>
<td>2.9</td>
<td>2.3</td>
<td>1.5</td>
<td>—</td>
<td>395 ± 3</td>
</tr>
<tr>
<td>Postanesthetic</td>
<td>8.2 ± 0.6</td>
<td>0.9</td>
<td>2.7</td>
<td>17.6</td>
<td>23.2</td>
<td>117.5</td>
<td>1.4</td>
<td>0.7</td>
<td>396</td>
</tr>
</tbody>
</table>

* Rats in this group were not anesthetized. Collection periods parallel those for anesthetized rats.
† P < 0.05, preanesthetic (days 3-6) vs. postanesthetic (day 7).
‡ P < 0.01, preanesthetic (days 3-6) vs. postanesthetic (day 7).
§ P < 0.05, postanesthetic (day 7) vs. postanesthetic, control group (day 7).
¶ P < 0.05, postanesthetic (day 7) vs. postanesthetic, control group (day 7).
were no significant differences among groups or among control animals except those that could be attributed to chance (tables 1 and 2). Rats anesthetized with methoxyflurane for 3 hours, Group II, developed slight nephrotoxicity. There was an increase in 24-hour urine output and a reciprocal decrease in urinary osmolality, but no change in BUN. Twenty-four hours after anesthesia, serum inorganic fluoride level was $76.3 \pm 8.0 \mu M$, a value consistent with slight nephrotoxicity (fig. 1). Mitochondrial swelling of proximal convoluted tubule cells was visible with electron microscopy. Rats anesthetized with methoxyflurane for one hour showed no abnormality. There also were dose-related increases in urinary inorganic and organic fluoride excretion (fig. 2, table 2).

Sevoflurane administration did not result in a renal defect. After one or four hours of anesthesia, there was no change in variables related to renal function. After 10 hours there was a significant decrease in urinary output, which probably was secondary to decreased solute excretion. However, BUN was unchanged in all groups, and no renal abnormality was seen with light or electron microscopy. Sevoflurane was defluorinated about a third to a fourth as much as methoxyflurane; there were dose-related increases in mean serum inorganic fluoride concentration and urinary inorganic and organic fluoride excretion. Fluoride levels returned towards preanesthetic values more quickly after sevoflurane than after methoxyflurane administration (fig. 1).

Of potential importance was the substantial weight loss observed in rats anesthetized with sevoflurane. Rats anesthetized for one hour lost 13 grams by the fourth day of the experiment; those anesthetized for 4 hours, 34 grams; those anesthetized for 10 hours, 38 grams. The latter two values are significantly greater than the weight loss which followed 3 hours of methoxyflurane (17 grams) or after no anesthesia (3 grams).

Fig. 1. Daily serum inorganic fluoride concentration after anesthesia. There were dose-related increases following administration of both drugs, with values after methoxyflurane considerably higher than after sevoflurane. Inorganic fluoride concentrations were still elevated four days after methoxyflurane anesthesia; by contrast, they had returned to normal 48 hours after sevoflurane administration.
PEAK SERUM FLUORIDE

Mean peak serum inorganic fluoride level following 4 hours of sevoflurane administration occurred 4 hours after anesthesia and was 29.1 ± 2.5 μM (fig. 3).

IN-VITRO STUDIES

Sevoflurane and methoxyflurane defluorinase specific activities were 1.69 ± 0.26 and 1.97 ± 0.47 nmol F-/30 min/mg protein, respectively. These values are not significantly different (P > 0.3).

Discussion

Sevoflurane has several properties of possible advantage in clinical anesthesia practice. Its blood-gas partition coefficient is 0.59 and its oil-gas partition coefficient is 42, so anesthetic induction and emergence should be rapid. This was verified by the present study. All rats were anesthetized within 2 to 3 minutes after introduction of 1.4 per cent sevoflurane into the chamber. Those anesthetized for 1 or 4 hours awakened and righted themselves within 1 or 2 minutes after anesthesia was discontinued; rats anesthetized for 10 hours righted themselves within 15 minutes after the end of anesthesia. Anesthetic induction with 0.5 per cent methoxyflurane required at least 30 minutes, and emergence after 3 hours of anesthesia required approximately an hour. Also, it is of practical importance that the vapor pressure and potency of sevoflurane are such that the Copper Kettle type of vaporizer, now employed for other inhalation agents, can be used for its administration.

Biochemical stability, that is, resistance to

![Graph showing urinary inorganic fluoride excretion after anesthesia.](http://anesthesiology.pubs.asahq.org/pdfaccess.ashx?url=/data/journals/jasa/931529/)

**Fig. 2.** Twenty-four-hour urinary inorganic fluoride excretion after anesthesia. Cumulative four-day excretion after methoxyflurane was three to four times greater than after sevoflurane. Elevated levels persisted longer after methoxyflurane anesthesia.
metabolic degradation, is a desirable property of anesthetic agents. This study employs production of inorganic fluoride as an index of biochemical stability. While this metabolic product has been shown to have clinical significance because of dose-related nephrotoxicity following methoxyflurane anesthesia, it may not be the only product of the biodegradation of inhalation anesthetics with significant biologic effect. Furthermore, until the stoichiometry of the degradation of fluorinated anesthetics is better described, the relationship between defluorination and extent of total metabolism will remain poorly defined.

The results of our in-cito study indicate that sevoflurane was defluorinated at a rate similar to methoxyflurane, the least stable of the fluorinated methylethyl anesthetic ethers. If biochemical stability were the only factor in defluorination of inhalation anesthetics, this would be an unacceptable defect. After methoxyflurane anesthesia, however, serum inorganic fluoride levels were more than six times higher and urinary inorganic fluoride excretion was three to four times greater than after comparable exposures to sevoflurane. The most likely explanation for the discrepancy between in-cito and in-cito sevo-

![Graph showing serum inorganic fluoride concentration following 4 hours of 1.4 per cent sevoflurane anesthesia. Inorganic fluoride concentration peaked 4 hours after anesthesia and declined rapidly. Decay curves for serum inorganic fluoride following methoxyflurane and enflurane anesthesia are taken from a previous study.]

flurane and methoxyflurane metabolic data is that the low tissue solubility of sevo-
flurane facilitated its rapid postanesthetic pulmonary excretion, whereas the greater solubility of methoxyflurane retarded its elimination. Therefore, sevoflurane was relatively unavailable during the postanesthetic period, the interval during which the majority of anesthetic metabolism occurs. In experiments in vitro, where reaction time was fixed at 30 minutes and the drugs were present in equimolar amounts, tissue solubility was not a significant factor in determining defluorination. Data from previous studies with enflurane support the conclusion that low tissue solubility may be the explanation for the differences in sevoflurane and methoxyflurane defluorination. In vitro, enflurane is defluorinated at about one seventh the rate of methoxyflurane, and therefore, it also should be defluorinated at approximately one seventh the rate of sevoflurane. Enflurane has a blood–gas partition coefficient of 1.9 and an oil–gas partition coefficient of 98; it is considerably more soluble than sevoflurane. However, inorganic fluoride excretion following enflurane anesthesia is approximately the same as that following sevoflurane. Although enflurane,
biochemically, is more stable than sevo-
flurane, its greater tissue solubility results in
slower elimination and, consequently, a
similar extent of defluorination.

Nephrotoxicity is related to the duration for
which high levels of inorganic fluoride are
maintained, as well as the absolute level.
Comparison of data from this and a previous
in-vivo study with enfurane (fig. 3) reveals
similar peak values and shapes of the inor-
ganic fluoride decay curves. Peak inorganic
fluoride levels after a lesser methoxyfluorane
exposure were higher and remained elevated
longer than after anesthesia with either of
the less soluble drugs. Thus, the nephrotoxic
potential of sevoflurane, due to its metabolism
to inorganic fluoride, should resemble
that of enfurane rather than that of
methoxyfluorane. In fact, in the present study,
there were no real abnormalities after as long
as ten hours of sevoflurane anesthesia. To
the contrary, as little as one to three hours of
methoxyfluorane has resulted in mild, poly-
uric, vasopressin-resistant nephrotoxicity, whereas six to ten hours of enfurane are
required to produce a similar lesion.  

The only apparent adverse effect following
sevoflurane administration was weight loss,
almost 10 per cent of total body weight in rats
anesthetized for 10 hours. Almost all of the
loss occurred during the first postanesthetic
day, when rats did not appear to feed well.
However, they did not regain the lost weight
during the next three days, when food and
water intake and activity returned towards
normal. Rats anesthetized with methoxy-
flurane for three hours lost an average of 26
grams the first postanesthetic day, regaining
9 grams by the fourth postanesthetic day.
This is the usual pattern in this type of
experiment. Liver and kidney sections ap-
peared normal, and no other gross abnor-
mality was apparent at the time of sacrifice. The
explanation for the weight loss is not clear.

The authors thank Messrs. G. Hernandez, J.
Scoggins, C.R. Williams, and J. Young, and Mrs. S.
Scoggins for skillful technical assistance.

References

1. Wallin RF, Napoli MD: Sevoflurane (fluoro-
methyl-1,1,1,3,3,3-hexafluoro-2-propyl ether): A new inhalational anesthetic

2. Mazze RI, Cousins MJ, Kosek JC: Dose-
related methoxyfluorane nephrotoxicity in
rats: A biochemical and pathologic correla-
tion. ANESTHESIOLOGY 36:571–587, 1972

3. Light TS, Mannion RF: Microdetermination of
fluoride in organic compounds by poten-
tiometric titration using a fluoride electrode.

4. Mazel P: General principles and procedures
for drug metabolism in vitro, Fundamentals
of Drug Metabolism and Drug Disposition.
Edited by BN La Du, HG Mandel, EL Way.
Baltimore, Williams and Wilkins, 1971, pp
527–546

5. Greenstein LR, Hitt BA, Mazze RI: Metabolism in vitro of enfurane, isoflurane
and methoxyfluorane. ANESTHESIOLOGY
42:429–434, 1975

comparison of the renal effects and
metabolism of enfurane and methoxyfluorane
in Fischer 344 rats. J Pharmacol Exp Ther
188:257–264, 1974

Neonatology

ERYTHROBLASTOSIS AND PROMETHA-
ZINE Promethazine hydrochloride has been
studied in animals in the laboratory and
found to be immunosuppressive. Its use
during pregnancies affected by erythroblas-
tosis is reported here. It has not been pos-
sible, with this small series of patients, to
prove unequivocally its effectiveness in
ameliorating the effects of this disease. How-
ever, it is believed that in some individual
cases beneficial results have occurred at the
dosage used. The probable mechanism of
action of this drug in vivo is metabolic sup-
pression of the fetal reticuloendothelial sys-
tem cells. (Gusdon, J. P.: Possible Ameliorat-
ing Effects of Erythroblastosis by Prometha-
zine Hydrochloride, Am J Obstet Gynecol
117:1101–1108, 1973.)